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Abstract 
Objective: To describe medication management among home-dwelling older adults. These data 
should allow us to identify potential problems and to indicate target areas for community pharmacist 
intervention.  
Design: Cross-sectional observational study 
Setting: Community pharmacies (n=86) in Belgium. 
Participants: Home-dwelling older adults using at least one chronic medicine (n=338). 
Measurements: Data on drug use were taken from the electronic pharmacy databases, while drug 
adherence was measured by pill count, self-report and estimation by GP and pharmacist. Drug 
knowledge and practical drug management capacity were assessed by patient interview and 
questionnaire, respectively.  
Results: The study population (n=338) used a median of 5 chronic drugs per patient. Half of our 
sample (n=169) used psychotropic medication chronically, mainly benzodiazepines. In 100 patients 
(29.6%) at least one drug-drug interaction of potential clinical significance was observed. The overall 
mean adherence per patient was very high (98.1%), but 39.6% of individuals was underadherent with 
at least one medication. Seventy-six % of patients had an acceptable knowledge of the indication for 
at least 75% of their medication. In nearly 15 % of the study population cognitive impairment was 
suspected by the Mini-Cog Test. The participants reported several practical problems with drug 
taking: difficulties with vision (32.0%), blister opening (12.1%), tablet swallowing (14.8%), tablet 
splitting (29.7% [represents % of patients who have to split tablets]) and distinction between 
different drug packages (23.4%). 
Conclusion: This study identified the following aspects of medication management by home-dwelling 
older adults that could be improved by pharmaceutical care services: (i) assistance of cognitively 
impaired patients, (ii) management of practical drug taking problems, (iii) DDI screening, (iv) drug 
adherence, and (v) chronic benzodiazepine use. 
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Introduction 
Older persons often suffer from several co-morbidities, and pharmacotherapy is a fundamental 
aspect of their disease management. However, older adults are at higher risk of adverse drug 
reactions (ADR) due to age-related pharmacokinetic and pharmacodynamic changes and 
polypharmacy (1). They are also more susceptible to non-adherence and to practical difficulties with 
medication taking such as cognitive impairment and various functional problems (2).  
The majority of older patients still live in their own homes and are responsible for their own 
medication management (3). Appropriate medication use – a key factor to maximize therapeutic 
benefits and to minimize the risk of ADRs – is known to be a major concern in this patient group. For 
example, Barat et al. performed interviews with 75-year-old home-dwelling persons in Denmark and 
found that more than 80% of them used three or more drugs, and that non-adherence was prevalent 
(20 to 70% depending on the measuring method) (4, 5). Tordoff et al. interviewed community-
dwelling people aged ≥75 years in New Zealand and observed problems with reading and 
understanding drug labels (9 and 4%, respectively) and leaflets (12 and 6%), and difficulty with 
swallowing solid dosage forms (14%) (6).  Community pharmacists are in the unique position of 
having frequent contact with ambulatory older patients at the time of medication purchase. This 
position enables pharmacists to assist them in their medication management, by using their drug-
related expertise to ensure that patients use their medicines appropriately (e.g., by facilitation of 
adherence, patient education to increase knowledge of the purpose of their medicines, resolving 
practical problems with drug taking). This is in line with the recent evolution of the pharmacist 
profession towards more patient-oriented activities (called “pharmaceutical care” or “clinical 
pharmacy”). However, community pharmacy-based studies investigating medication management of 
home-dwelling elderly are rare. The already published pharmacy studies report on home-based 
medication reviews aimed at improving the appropriateness of prescribing (7-11).  
The present observational community pharmacy-based study aimed to describe medication 
management among home-dwelling older adults using at least one chronic medicine, by examining: 
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(i) types of drugs used and presence of drug-drug interactions, (ii) drug adherence, (iii) patient 
knowledge of the purpose of their drugs and (iv) practical drug management capacity. These data 
should allow us to identify potential problems and to indicate target areas for community pharmacist 
intervention.  
 
Method 
Study design 
This cross-sectional observational study was carried out from December 2008 till May 2009 in 86 
randomly selected community pharmacies in Flanders (the Dutch-speaking northern part of 
Belgium). Approval for the study was granted by the Ethics Committee of the Ghent University 
Hospital, and all patients gave written informed consent. The patients’ general practitioners were 
informed about the purpose of the study. 
 
Patients 
In consecutive order, older patients visiting the pharmacies were invited to participate in the study 
when fulfilling the following inclusion criteria: (i) aged 70 years or older, (ii) using at least one chronic 
medicine (≥90 defined daily doses (DDD) per year), (iii) home-dwelling, (iv) ambulatory (i.e., 
personally collecting their medication at the pharmacy), and (v) regular clients of the pharmacy. 
From each of the pharmacies, four patients were planned to be recruited. 
 
Data collection 
Patient characteristics 
At inclusion, patients completed a questionnaire collecting socio-demographic characteristics, the 
number of GP visits and the number of home visits by a home nurse. Cognitively impaired patients 
were assisted by a relative or caregiver when completing this questionnaire.  
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Types of drugs used and presence of drug-drug interactions (DDIs) 
Each patient’s current chronic medication regimen (≥ 90 DDD/year) was taken from the electronic 
patient records at the community pharmacy. All chronic medicines were categorized according to the 
Anatomical Therapeutic Chemical (ATC) classification system. All chronic drugs were also screened 
for drug-drug interactions (DDIs) using Lexi-Interact® software (Lexi-Comp). Only potentially severe 
interactions (classified as ‘consider therapy modification’ or ‘avoid combination’) were included in 
the Results section. Delphi Care software (Belgian Pharmacist Association) was used for interaction 
analysis of drugs marketed in Belgium but not listed in Lexi-Interact®.  
 
Drug adherence 
Adherence to chronic medication was measured by pill count. For every chronic medicine, the daily 
dose prescribed was asked to the treating physician and pills were counted at two home visits 
performed with a 4 week-interval. The number of pills actually taken during this interval was divided 
by the number of pills that should have been taken (according to the prescribed dosing regimen) and 
was expressed as adherence rate (%). For each patient, mean adherence was calculated by summing 
adherence percentage for all chronic drugs and then dividing the sum by the number of chronic 
drugs the patient was taking. Patients were considered as underadherent when having at least one 
medication with adherence <80%.  
In addition, overall adherence was self-reported by the participants, and estimated by pharmacists 
and GP’s on a scale ranging from 0 to 5 (with 5 indicating 100% adherence). 
 
Drug knowledge 
The patients’ knowledge about the indication of their chronic medication was evaluated by asking for 
drug indications (“Do you know why you have to use this medicine?”). Their drug understanding was 
classified as correct (when reporting the correct indication or the correct target organ), wrong or no 
knowledge. Correct answers scored 1 point, the other answers scored zero. The patients’ drug 
7 
 
knowledge was then calculated by dividing the number of points scored by the number of drugs 
used. We considered patients scoring a ratio of 0.75 or more as having acceptable knowledge of their 
medication. This cut-off value of 75% was already used by other investigators (5, 12). 
 
Practical drug management capacity 
At inclusion, patients completed a questionnaire collecting the following items: medication 
management tool use (e.g., pill organizer), medication management assistance, self-reported visual 
and cognitive impairment, and self-reported problems with tablet swallowing, tablet splitting, blister 
opening and distinction between different drug packages. In addition, the participants’ cognitive 
impairment was assessed by subjecting them to the Mini-Cog Test. This validated test combines two 
simple cognitive tasks (three-item word memory and clock drawing) as a brief screening test for 
cognitive impairment (13).  
 
Statistical analysis 
Stepwise backward logistic regression was performed to identify patient-related predictors of 
underadherence (i.e., having at least one medication with <80% adherence), using R software 
(version 2.12.0). We started from a model with main effects only. From this model, non-significant 
factors were consecutively removed. When statistically significant predictors were found, a two-way 
interaction test was performed.  
 
Results 
In the 86 participating pharmacies, 840 potentially eligible patients were screened. Three hundred 
patients (35.7%) were excluded: 135 (45.0%) were younger than 70 years, 50 (16.7%) did not collect 
the medication from the pharmacy by themselves, 54 (18.0%) were no frequent clients of the 
pharmacy, 47 (15.7%) did not use chronic medication, and 14 (4.7%) were not home-dwelling. 
Among the 540 patients who matched the inclusion criteria, 202 (37.4%) refused to participate in the 
8 
 
study for several reasons:  no interest (n=102; 50.5%), deprivation of privacy (n=33; 16.3%), lack of 
time (n=27; 13.4%), poor health status (n=12; 5.9%) and other reasons (n=28; 13.9%). 
 
Patient characteristics and social medical status 
The baseline characteristics of the 338 included patients are described in Table 1. Most of the 
participants were aged between 70 and 80 years. About 60% of the patients lived together with a 
partner or family member(s), while 40% lived alone. Most patients (53.6%) consulted their general 
practitioner (GP) once a month.  
 
Types of drugs used and presence of DDIs 
The 338 participants in this study used a total of 1889 chronic medicines, with a median of 5 per 
patient (IQR 4-7). Thirty-nine percent (n=133) of the population consumed 1 to 4 chronic drugs, 
47.0% (n=159) 5 to 8 drugs and 13.6% (n=46) 9 or more drugs. The most frequently used medicines 
were lipid modifying drugs, antithrombotics, agents acting on the renin-angiotensin system, 
psycholeptics and beta-blockers (Table 2). Half of our sample used psychotropic medication (N05 
and/or N06) chronically (n=169, 50.0%), with 56 of them (56/169, 34.9%) consuming 2 or more 
psychotropics concurrently. Thirty psychotropic users (30/169, 17.8%) were identified as having 
potential cognitive impairment (by Mini-Cog). The most common class of psychotropics was 
benzodiazepines (used by 34.3% of the total population), followed by antidepressants (used by 14.8% 
of the total population) and benzodiazepine-related drugs (ATC: N05CF) (used by 8.6% of the total 
population). Twenty-three benzodiazepine users were on long-acting benzodiazepines.  
Fifty-nine percent (n=198) of the study population had purchased non-prescribed over-the-counter 
medication or dietary supplements during the past year. The most commonly used non-prescribed 
products were: respiratory drugs (mainly cough suppressants and nasal preparations for topical use), 
alimentary tract drugs (mainly laxatives), analgesics (mainly paracetamol) and dietary supplements 
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(used by 58.3%, 31.1%, 26.6% and 20.7% of the total population, respectively). Ten percent of 
participants (n=34) reported taking dietary supplements from the supermarket. 
In total, we found 140 potentially severe DDIs in the chronic medication regimens. In 100 patients 
(29.6%) at least one DDI of potential clinical significance was observed. The maximum number of 
potentially severe DDIs found per patient was 5. The most frequently occurring DDIs are shown in 
Table 3. Drugs or drug classes most frequently involved in DDIs were: amiodarone (n=23), statins (or 
HMG CoA reductase inhibitors) (n=22), beta-blockers (n=22), serotonin modulating drugs (n=21) and 
NSAIDs (n=14). In 7 patients, we found a clinically important DDI between non-prescription and 
chronic medication (i.e., concurrent use of aspirin or NSAID with vitamin K antagonist or SSRI). 
 
Drug adherence 
The overall mean adherence per patient was 98.1%. However, we found that 134 patients (39.6%) 
were underadherent with at least one medication. According to the regression model, 
underadherence was predicted by: the number of medications used (OR 1.21; 95% CI 1.11 to 1.33 for 
each 1-unit increase in number of medications; p<0.001), living situation (living with partner/family 
vs. living alone) (OR 0.55; 95% CI 0.34 to 0.89; p<0.05), swallowing problems (OR 2.36; 95% CI 1.24 to 
4.56; p<0.01), medication management assistance (OR 0.47; 95% CI 0.22 to 0.96; p<0.05), cognitive 
impairment indicated by the Mini-Cog Test (OR 1.99; 95% CI 1.00 to 3.98; p<0.05), and patient self-
report of sometimes stopping medication on own initiative (OR 2.44; 95% CI 1.32 to 4.56; p<0.01).     
Most patients (95.9%, n=324) self-reported to take their medicines according to the GP’s 
instructions, although nearly one fifth (n=82) admitted forgetting medicine intake occasionally. 
Moreover, 16.9% (n=57) admitted having stopped a medication on their own initiative. The 
pharmacists’ and GPs’ estimates about their patients’ overall drug adherence were very similar: a 
median adherence of 4 (on a scale from 0 to 5) was estimated by pharmacists as well as by GPs.  
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Drug knowledge 
Seventy-six percent (n=258) of the participants had an acceptable knowledge of the indication for at 
least 75% of their medication. Correct indications were most common among gastrointestinal drugs. 
Wrong indications were most common among urogenital drugs and anticoagulants (Table 4). 
 
Practical drug management capacity 
Approximately 10% (n=29) of the participants self-reported to suffer from cognitive impairment, 
while in nearly 15 % (n=49) cognitive impairment was suspected by the Mini-Cog Test (Table 5). Only 
12 of the 49 persons with positive Mini-Cog (24.5%) had self-reported cognitive impairment. Almost 
one third of the study population reported to have visual problems. Other self-reported difficulties 
refer to blister opening (12.1%), tablet swallowing (14.8%), tablet splitting (29.7% [represents % of 
patients who actually split tablets]) and distinction between different drug packages (23.4%) (Table 
5). 
Half of the participants reported to use a medication management tool, with the pill organizer being 
the most frequently used (Table 5). The majority of our population did not receive assistance in their 
medication management (n=286; 84.6%). Only 18 of the 49 persons with positive Mini-Cog (36.7%) 
received medication management assistance. 
 
Discussion 
Types of drugs used and presence of DDIs 
We found that the prevalence of polypharmacy was high, with two thirds of the home-dwelling older 
adults using five or more chronic medicines. A striking finding is the common long-term use of 
psychotropic drugs, mainly benzodiazepines. The rate of benzodiazepine use in this study (35.5%) 
was considerably higher than that observed in previous studies carried out amongst community-
dwelling older adults in Europe and USA (ranging from 6.4% to 15.3%) (14-17), though similar to the 
rate of 31.9% reported by Fourrier et al. (in France) (18). According to the International Narcotics 
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Control Board (INCB), Belgium is one of the leading consumers of benzodiazepines worldwide (19). It 
is well documented that continued use of benzodiazepines may lead to dependence, and is 
associated with an increased risk of accidents/falls and cognitive function impairment (20). 
Therefore, current guidelines advocate a conservative prescription policy, especially with respect to 
long-term prescription (21). Our data demonstrate that these recommendations are not yet fully 
implemented in Belgian practice.  
About 30% of the study population was exposed to drug combinations at risk of potentially severe 
DDIs. In literature, the prevalence of potential DDIs in community-dwelling older adults ranges from 
4% to 46% (22-26). It is important to note that we screened for potential DDIs using DDI software, 
without knowing whether the interaction actually resulted in an adverse effect for the patient. A 
recent study showed that computerized screening overestimates considerably in identifying clinically 
relevant DDIs: only 7% of DDIs detected by computerized screening were recorded using prospective 
bedside screening, despite the fact that an active search was undertaken by clinical pharmacists (27). 
This means that each potentially severe DDI flagged by the pharmacy or physician software should be 
evaluated case-by-case for its clinical relevance, taking into account drug dosage and duration of 
therapy, severity and frequency of the ADR related to the DDI, and patient-related risk factors (28). 
 
Drug adherence 
The overall patient adherence was very high. Prior studies reported rates ranging from 26% to 59% 
(29). Our higher adherence rate might be due to a positive selection bias, since patients participated 
voluntarily in the study (without payment) and were regular pharmacy customers (this was done 
intentionally, in order to maximize the completeness of the computerized pharmacy records). These 
selection criteria might reflect a higher medication adherence. Moreover, examining overall patient 
adherence could be misleading as it may mask non-adherence with one or few drugs (especially in 
polypharmacy patients). Indeed, we found that underadherence with at least one medicine was 
present in 40% of individuals. 
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Drug knowledge 
About three-quarters of the participants could describe the indication of at least 75% of their 
medicines correctly. This figure is in agreement with a recent study performed among older patients 
in Swedish primary care (71%) (12), but higher than that observed in a Danish study conducted in the 
late nineties (60%) (5). This recent increase in drug knowledge might result from the trend of 
increased interaction between patient and healthcare provider and the easier access to health 
information.  
 
Practical drug management capacity 
We found that most of our patients with suspected cognitive impairment managed their medication 
alone, without help from family or caregiver. About half of participants used a medication 
management tool, which is considerably less than in the USA (82%) (30). However, adherence aids 
(e.g., pill organizers) can improve drug adherence (31-33). Practical problems with medicine-taking 
(distinction between different drug packages, tablet swallowing and splitting, blister opening) were 
common. Many of these could easily be resolved by health professionals by proactive enquiry. 
 
Potential community pharmacist roles 
Based on the results of this study, five target areas for community pharmacist intervention were 
identified. First, although our study population consisted of ambulatory home-living older adults, still 
15% was suspected as cognitively impaired (by Mini-Cog) and most of them did not receive help in 
managing their medicines. The Mini-Cog is a simple and effective tool to uncover cognitive 
impairment, which is suitable for application in pharmacy practice. Patients with cognitive 
impairment warrant extra pharmaceutical care (e.g., clear verbal and written information using 
simple language, introduction of reminder strategies, and involvement of family member or home 
nurse). Second, pharmacists should routinely ask older patients about practical drug taking problems. 
For example, difficulties with tablet swallowing can often be overcome by switching to alternative 
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galenic forms or medications that can be crushed or capsules that can be opened. Third, community 
pharmacists should play an important role in screening for potentially severe DDIs, since they have 
an integrated view on the patient’s medication history (including OTC-products and medication 
prescribed by different physicians). This requires availability of improved DDI software with clinical 
decision support (34) and sufficient pharmacist training on drug- and patient-related risk factors for 
DDI occurrence. Fourth, a substantial number of participants was underadherent with at least one 
medication. Pharmacists should alertly follow up older patients at risk for underadherence and 
intervene when necessary. A systematic review of George et al. advised to use combinations of 
educational and behavioural strategies to improve medication adherence in older patients (35). Fifth, 
pharmacists could assist GPs in applying a minimal intervention strategy to reduce chronic 
benzodiazepine use (i.e., sending of a discontinuation letter). Such minimal intervention has been 
proven effective in short- and long-term (36, 37). Nevertheless, the sending of letters to chronic 
users has not been incorporated in routine primary care. Practical assistance by the community 
pharmacist may improve implementation. By using their electronic dispensation records, pharmacists 
can easily identify chronic benzodiazepine users and transfer these data to the GP. A recent pilot 
study conducted in The Netherlands evaluated such joint pharmacist and GP intervention as a 
practical and effective way to reduce benzodiazepine use (38) 
 
Study limitations 
Our patients might not be fully representative of the overall general population of community 
dwelling older adults with chronic diseases, since they participated voluntarily in the study and were 
regular pharmacy customers taking at least one chronic medicine. This means that our data might 
reflect an underestimation of the problems in real world, and an overestimation of drug use 
patterns, such as for benzodiazepines. In addition, it is likely that the prevalence of impairments is 
higher in the general old population as we only included ambulatory older patients (i.e. still able to 
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visit the pharmacy). Also the fact that we evaluated drug taking problems by questionnaire and not 
by direct assessment may have led to an underestimation of these problems.   
We did not perform a formal evaluation of the quality of prescribing, as we intended to focus on 
problems that can be tackled by basic community pharmacy services. In Belgium (as in most other 
European countries), implementation of pharmaceutical care is still in development. Thus, finding a 
basic and feasible intervention was our primary objective.  
 
Conclusion 
This observational study identified several aspects of medication management by home-dwelling 
older adults that could be improved by pharmaceutical care services: (i) assistance of cognitively 
impaired patients, (ii) management of practical drug taking problems, (iii) DDI screening, (iv) drug 
adherence, and (v) chronic benzodiazepine use. 
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TABLES 
 
Table 1: Patient characteristics (n = 338). 
 n (%) 
Male sex 157 (46.4) 
Age 
70-80 y 
81-90 y 
>90 y 
 
234 (69.2) 
100 (29.6) 
4 (1.2) 
Education, stopped school at 
≤ 15y 
16-18 y 
>18 y 
 
144 (42.6) 
124 (36.7) 
70 (20.7) 
Current living arrangement 
Alone 
With partner 
With family member 
 
133 (39.3) 
194 (57.4) 
11 (3.3) 
Frequency of GP visits 
1x/week 
2x/month 
1x/month 
1x/trimester 
1x/year 
 
9 (2.7) 
40 (11.8) 
181 (53.6) 
86 (25.4) 
22 (6.5) 
Frequency of home visits by home nurse 
Never 
Sometimes 
Often 
 
274 (81.1) 
34 (10.1) 
30 (8.9) 
GP = general practitioner 
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Table 2: Most frequently used chronic medicines (classified according to ATC level 2).  
 
ATC Code ATC Class Name 
% of total number of 
chronic medicines 
(n = 1889) 
% of study population 
using this medicine 
(n = 338) 
C10 Lipid modifying agents 10.7 58.0 
B01 Antithrombotic agents 10.7 51.5 
C09 Agents acting on the renin-angiotensin system 9.6 50.0 
N05 Psycholeptics 8.6 41.7 
C07 Beta blocking agents 8.0 44.4 
A10 Drugs used in diabetes 5.2 19.8 
C08 Calcium channel blockers 4.8 26.3 
C03 Diuretics 4.8 25.7 
R03 Drugs for obstructive airway diseases 4.6 13.0 
C01 Cardiac therapy 4.4 18.9 
A02 Drugs for acid related disorders 4.3 22.2 
N06 Psychoanaleptics 4.3 19.8 
ATC = Anatomical Therapeutic Chemical  
 
 
 
 
 
 
 
Table 3: Top 5 of most frequently occurring potentially severe drug-drug interactions (DDIs). 
 
Interacting drug pair 
Prevalence 
n (%)
*
 
Potential interaction effect 
Beta-blockers + Alfa2-agonists 12 (8.6) 
Beta-blockers may enhance the rebound 
hypertensive effect of alfa2- agonists, 
when the alfa2- agonist is abruptly 
withdrawn. 
Amiodarone + HMG-CoA reductase inhibitors                  
(except: pravastatin) 
11 (7.9) Amiodarone may decrease the metabolism 
of HMG-CoA reductase inhibitors. 
ACE Inhibitors + Allopurinol 9 (6.4) 
ACE inhibitors may enhance the potential 
for allergic or hypersensitivity reactions to 
allopurinol. 
Simvastatin + Diltiazem 8 (5.7) Diltiazem may increase the serum 
concentration of simvastatin. 
Serotonin modulator + Serotonin modulator 8 (5.7) Risk of serotonin syndrome. 
  * 
Percentages represent % of all potentially severe DDIs observed in the study population. 
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Table 4: Patients’ knowledge of medicine’s indication, classified per drug class. 
 
Drug Class 
Indication correct 
n (%) 
Indication wrong 
n (%) 
Indication unknown 
n (%) 
Gastrointestinal (ATC-A) (n = 187) 
Anticoagulants (ATC-B) (n = 203) 
Cardiovascular (ATC-C) (n = 800) 
Urogenital (ATC-G) (n = 27) 
Systemic Hormones (ATC-H) (n = 32) 
Musculoskeletal (ATC-M) (n = 98) 
Central Nervous System (ATC-N) (n = 313) 
Respiratory (ATC-R) (n = 113) 
174 (93.0) 
159 (78.3) 
623 (77.9) 
22 (81.5) 
26 (81.3) 
80 (81.6) 
260 (83.1) 
93 (82.3) 
3 (1.6) 
29 (14.3) 
69 (8.6) 
4 (14.8) 
4 (12.5) 
7 (7.1) 
37 (11.8) 
5 (4.4) 
10 (5.3) 
15 (7.4) 
108 (13.5) 
1 (3.7) 
2 (6.3) 
11 (11.2) 
16 (5.1) 
15 (13.3) 
 
 
 
 
 
Table 5: Practical drug management capacity. 
 
 
N = 338 
Cognitive impairment 
Self-reported
*
  
According to Mini-Cog Test 
 
29 (8.6) 
49 (14.5) 
Visual impairment (self-reported
**
) 108 (32.0) 
Self-reported difficulties with 
Blister opening 
Tablet swallowing 
Tablet splitting 
Distinction between different drug packages 
 
41 (12.1) 
50 (14.8) 
49 (29.7)
†
 
79 (23.4) 
Medication management tool use 
None 
Pill organizer 
Medication scheme 
Pill organizer + medication scheme 
Other 
 
168 (49.7) 
99 (29.3) 
33 (9.8) 
14 (4.1) 
24 (7.1) 
Medication management assistance 
None 
By partner 
By family member 
By nurse 
By other person 
 
286 (84.6) 
33 (9.8) 
10 (3.0) 
7 (2.1) 
2 (0.6) 
Data are presented as n (%). 
*   “Do you have severe memory problems?” 
** “Do you have vision problems, even if you are wearing glasses?” 
† Percentage represents % of those patients who actually split tablet(s). 
 
 
 
